ONCAlert | Upfront Therapy for mRCC

Latest NewsMORE >>

Bemcentinib in combination with pembrolizumab demonstrated clinical efficacy in the stage 1 portion of a phase II trial, which evaluated the combination in patients with non–small cell lung cancer who progressed on prior immune checkpoint inhibition, meeting the primary end point of the study.

Coverage from the 2020 ASCO Gastrointestinal Cancers Symposium Learn More >>

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.